Detection of fluoroquinolone-induced tendon disorders using a hospital database in Japan

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 8, 2012, Pages 886-889

  Hori, Katsuhito ^a   Yamakawa, Kasumi ^a   Yoshida, Naoko ^b   Ohnishi, Kazunori ^a   Kawakami, Junichi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Adverse drug reaction; Fluoroquinolone; Hospital database; Pharmacoepidemiology; Tendinitis; Tendon disorder; Tendon rupture

Indexed keywords

CEPHALOSPORIN; CIPROFLOXACIN; FLEROXACIN; GARENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PRULIFLOXACIN; QUINOLONE DERIVATIVE; SITAFLOXACIN; SPARFLOXACIN; TOSUFLOXACIN;

ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG DETERMINATION; HOSPITAL PATIENT; HUMAN; JAPAN; MAJOR CLINICAL STUDY; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; RISK; TENDON DISEASE; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; FEMALE; FLUOROQUINOLONES; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; MUSCULAR DISEASES; RISK ASSESSMENT; TENDINOPATHY;

EID: 84864333468     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3285     Document Type: Article

References (10)

1. Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996; 41: 277-284. DOI: 10.1046/j.1365-2125.1996.03013.x.
2. Van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002; 324: 1306-1307. DOI: 10.1136/bmj.324.7349.1306.
3. Tendon disorders with quinolone antibiotics. Prescriber Update Nov 2007; 28(1). [7 February 2011].
4. FDA. Fluoroquinolone antimicrobial drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]. Information for Healthcare Professionals 2008. [7 February 2011].
5. Khaliq Y, Zhanel GG. Musculoskeletal injury associated with fluoroquinolone antibiotics. Clin Plast Surg 2005; 32: 495-502. DOI: 10.1016/j.cps.2005.05.004.
6. Van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003; 163: 1801-1807. DOI: 10.1001/archinte.163.15.1801.
7. Kimura M, Tani S, Watanabe H, Naito Y, Sakusabe T, Watanabe H, Nakaya J, Sasaki F, Numano T, Furuta T, Furuta T. High speed clinical data retrieval system with event time sequence feature: with 10years of clinical data of Hamamatsu University Hospital CPOE. Methods Inf Med 2008; 47: 560-568. DOI: 10.3414/ME9125.
8. Harrell RM. Fluoroquinolone-induced tendinopathy: what do we know? South Med J 1999; 92: 622-625. DOI: 10.1097/00007611-199906000-00014.
9. Williams RJ 3rd, Attia E, Wickiewicz TL, Hannafin JA. The effect of ciprofloxacin on tendon, paratendon, and capsular fibroblast metabolism. Am J Sports Med 2000; 28: 364-369.
10. Shakibaei M, Souza P, Sickle D, Stahlmann R. Biochemical changes in Achilles tendon from juvenile dogs after treatment with ciprofloxacin or feeding a magnesium-deficient diet. Arch Toxicol 2001; 75: 369-374. DOI: 10.1007/s002040100243.